Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 1, 2024
Distillery Therapeutics

Inhibiting ALKBH5-mediated demethylation for depression

BioCentury | Jun 27, 2019
Distillery Therapeutics

An insulin-conjugated dual SLC2A1/SLC2A4 inhibitor for diabetes

BioCentury | Sep 28, 2018
Targets & Mechanisms

Cell metabolism’s migration

Why ECM remodeling pathways could be the source of new cancer metabolism targets
BioCentury | May 15, 2018
Distillery Therapeutics

Autoimmune disease

BioCentury | Apr 27, 2015
Clinical News

Triheptanoin: Clinical trial data

BioCentury | Apr 23, 2015
Top Story

Ultragenyx gains on De Vivo results

BioCentury | Nov 10, 2014
Clinical News

Triheptanoin regulatory update

Items per page:
1 - 10 of 17